Business Context and Reporting Period
This Form 8-K Current Report, filed on November 3, 2021, covers events occurring on October 28, 2021, and November 3, 2021, for Cara Therapeutics, Inc. (Note: The request metadata listed "Tvardi Therapeutics," but the filing text identifies the registrant as Cara Therapeutics, Inc.). The report details a significant leadership transition as the company prepares to launch and commercialize its product KORSUVA (CR845/difelikefalin).
Key Financial Metrics
This filing is a current report regarding executive compensation and does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data provided relates to executive compensation packages:
- Christopher Posner (New CEO):
- Annual Base Salary: $680,000
- Signing Bonus: $400,000 (paid in two installments)
- Target Annual Bonus: 60% of base salary
- Equity: $100,000 Initial RSU Award; Option to purchase 566,000 shares; RSUs for 142,000 shares.
- Derek Chalmers (Outgoing CEO):
- Severance: 12 months of base salary
- Bonus: Full 2021 Target Bonus
- Equity: Accelerated vesting for time-based equity vesting within 12 months post-employment.
Material Changes
The primary material change is the departure of Derek Chalmers, Ph.D., as President, CEO, and Director, effective November 8, 2021. He will transition to a Senior Advisor role through June 30, 2022. Simultaneously, Christopher Posner, a current non-employee director, was appointed President and CEO, effective November 9, 2021.
Outlook, Risks, and Contingencies
Management Commentary: The leadership change is described as a mutual decision driven by the company's need for a transformative approach as it prepares to launch and commercialize KORSUVA.
Compensatory Contingencies:
- Posner Severance: If terminated without Cause or resigns for Good Reason, he receives 12 months of salary, COBRA, prorated bonus, and 12 months of accelerated equity vesting. In a Change of Control scenario followed by termination, benefits increase to 18 months of salary, 1.5x target bonus, and full equity acceleration.
- Chalmers Severance: Includes 12 months of salary, COBRA, full 2021 bonus, and accelerated vesting of time-based equity that would have vested in the subsequent 12 months. Performance-based RSU milestones are extended to March 31, 2022.
Investor Verification Checklist
- Verify the exact vesting schedules and performance milestones for the new CEO's equity awards (Options and RSUs) in the full Employment Agreement (Exhibit 10.1).
- Confirm the specific dollar value of the "Target Bonus" for the outgoing CEO to calculate total severance liability.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the commercialization of KORSUVA.
- Monitor future filings for the impact of these compensation costs on the company's cash burn rate and liquidity position.